logo-loader
RNS
Apollon Formularies PLC

Apollon Formularies Plc - Issue of Equity

5 February 2024

Apollon Formularies Plc

("Apollon" or the "Company")

Issue of Equity

Apollon Formularies plc (AQSE: APOL), a based international pharmaceutical company trading on the Aquis Growth Market Stock Exchange, is pleased to announce that the Company has issued 18,000,000 Ordinary Shares in, in lieu of cash, in settlement of fees at a deemed price of £0.001 per share for a total value of £18,000.UK

Application will be made for the new Ordinary Shares to be admitted to trading on the Aquis Growth Market and admission to trading is expected in the new Ordinary Shares on or about8 February 2024. 

Following this issue, the Company has 789,191,266 Ordinary Shares in issue, each share carrying the right to one vote. The figure of 789,191,266 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

The Directors of the Company accept responsibility for the contents of this announcement.

ENDS

For additional information, please visit or contact:www.apollon.org.uk

Tel:                                         +44 771 198 0221Apollon Formularies                                                     

Stene Jacobs                     stene@apollon.org.uk

Peterhouse Capital Limited (Corporate Adviser)               

Tel:                                         +44 207 220 9795

Guy Miller                          gm@peterhousecapital.com

About Apollon and Apollon Jamaica

Apollon Formularies plc is an international medical cannabis and medicinal mushroom pharmaceutical company headquartered in the . Apollon Formularies Jamaica Limited is a pharmaceutical company incorporated and operating in the Commonwealth of since 2016. Apollon Jamaica is licensed by the Jamaican government's Cannabis Licensing Authority (CLA) to cultivate (R&D), perform research and development, process, and sell medical cannabis therapeutic products that include legal medical cannabis to treat various illnesses under medical supervision.United KingdomJamaica




NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read